Hims Hers Health Inc (HIMS) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Hims Hers Health Inc $5.41, price $28.39, upside -80.9%, quality 34 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value $5.41 · Strongly overvalued (−81%)
!Quality 34/100
✓Healthy Growth(revenue 5y +73.6 %/yr)
!Loss over the last twelve months · -0.6% net margin (TTM) · fiscal year 2025 5.5%
!High debt · generates free cash flow
!Trails peers(0/13)
!Narrow moat31/100
!Insider activity44/100
!Evidence only low, so the estimate is less certain
Watch Hims Hers Health Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $3.11 – $68.74 · fair‑value band $2.90 – $7.92 · the $28.39 price screens above the $5.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Hims Hers Health in your weekly email
Every Wednesday you see whether Hims Hers Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.
Show more
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
Stock analysis
Hims Hers Health Inc (HIMS) currently trades at $28.39, while our model-based Fair Value estimate is $5.41, implying the stock looks roughly 424.7% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $26.73 per share, and 0 of the 23 models we run sit above the $28.39 price.
Bear case: the Economic Profit group reads lowest at $1.15, and 23 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: $2.90 (bear) to $7.92 (bull), the price of $28.39 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Hims Hers Health Inc reported revenue of $2.3B in FY2025 versus $272M in FY2021, a compound +71.4%/yr. Reported net income was $128M in FY2025.
Key figures
Market cap $7.3B · P/S ratio 3.29 · EPS (TTM) $−0.0800 · Net margin 5.5% · Return on equity −2.7% · Return on assets (EBIT) −7.8% · Operating margin −7.9% · Revenue (TTM) $2.4B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (medium confidence).
What moves the price
The share trades about 55% below its 52-week high and 96% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −81%, HIMS screens richer than that median.
Fair Value models
Bear $2.90Fair Value $5.41Bull $7.92
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+59.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+73.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+89.6%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.2% (2020) → 4.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+49.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +46.3% a year for the price.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 0/12 measures
Overall it trails its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside−81% · Bottom 25%
Profitability
Return on assets1% · Below median
Net margin (TTM)−1% · Below median
Operating margin (TTM)−8% · Bottom 25%
Growth and dividend
Revenue growth4% · Below median
Balance sheet
Debt / equity1.80× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B13.55× · Priciest 25%
P/S (TTM)3.09× · Pricier than median
P/FCF99.1× · Priciest 25%
EV/EBITDA96.8× · Priciest 25%
PEG2.15× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)19· sector 21
PAST (return on equity)0· sector 27
HEALTH (low debt)10· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hims Hers Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/HIMS
Frequently asked questions
Is Hims Hers Health Inc (HIMS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $5.41 versus a price of $28.39, about −81% upside (overvalued).
What is the fair value of HIMS?
Our model-based fair value for Hims Hers Health Inc is $5.41 (as of Sep 23, 2026), built from audited fundamentals. The current price: $28.39.
What is the quality score of HIMS?
Hims Hers Health Inc has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hims Hers Health Inc (HIMS)?
Our model-based price target is the fair value of $5.41 (as of Sep 23, 2026) from 23 valuation models. Cautious scenario $2.90, optimistic scenario $7.92. It is a calculation from audited fundamentals, not an analyst target.
What is the Hims Hers Health Inc stock forecast for 2026?
Our models put fair value at $5.41, about −81% upside versus a price of $28.39 (overvalued). Cautious scenario $2.90, optimistic scenario $7.92. The calculation is refreshed regularly with new filings.
What is the revenue of Hims Hers Health Inc (HIMS)?
Hims Hers Health Inc reported trailing-twelve-month revenue of about $2.4B (latest available figure, as of Sep 23, 2026).
What growth is priced into Hims Hers Health Inc (HIMS)?
For today's price to be fair in a discounted-cash-flow model, Hims Hers Health Inc would have to grow free cash flow by +49.8 % per year for five years (discount rate 12.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +73.6 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of HIMS use?
Our models discount Hims Hers Health Inc at 12.2 %: a base by market capitalisation (mid), damped by beta 2.34, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hims Hers Health Inc that is +49.8 % per year a year over ten years, using the same discount rate (12.2 %) and the same formula as our fair value.
How much growth has Hims Hers Health Inc (HIMS) delivered so far?
Over the past 5 years revenue at Hims Hers Health Inc grew +73.6 % a year. The price currently implies +49.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hims Hers Health Inc (HIMS) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Hims Hers Health Inc (+49.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hims Hers Health Inc (HIMS)?
The free-cash-flow yield on the price is 1.01 %: that much free cash flow Hims Hers Health Inc produces per unit of market value. When it exceeds the discount rate of our models (12.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hims Hers Health Inc (HIMS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hims Hers Health Inc it is $5.41 per share (as of Sep 23, 2026), against a price of $28.39. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Hims Hers Health Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, HIMS trades above its calculated fair value: price $28.39, fair value $5.41, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HIMS?
No. The price is what the market pays today ($28.39); the fair value is what the company's own numbers justify ($5.41). For Hims Hers Health Inc the two are $22.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hims Hers Health Inc worth?
The market values Hims Hers Health Inc at about $7.3B (market capitalisation, as of Sep 23, 2026). Per share that is $28.39; our models calculate a fair value of $5.41 per share.
What do the bullish and bearish scenarios say about HIMS?
Our models span a range for Hims Hers Health Inc: cautious scenario $2.90, base $5.41, optimistic $7.92 per share (as of Sep 23, 2026, price $28.39). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of HIMS?
The PEG ratio of Hims Hers Health Inc is 2.15 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Hims Hers Health Inc (HIMS)?
Balance-sheet figures for Hims Hers Health Inc (as of Sep 23, 2026): return on equity −2.7%, debt of 1.80 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is HIMS from its 52-week high?
Hims Hers Health Inc trades at $28.39, about 55% below its 52-week high of $62.76 and 96% above the low of $14.52 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $5.41 is for.
Which stocks are comparable to Hims Hers Health Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hims Hers Health Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $28.39, calculated fair value $5.41 (−81%), Quality Score 34/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HIMS calculated?
We run Hims Hers Health Inc through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $5.41, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Hims Hers Health Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hims Hers Health Inc (HIMS)?
The closing price on Sep 23, 2026 was $28.39. Our model-based fair value is $5.41, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hims Hers Health Inc right now?
The price sits above even our optimistic bull case ($7.92). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($2.90 to $7.92). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Hims Hers Health Inc
How large is the market capitalisation of Hims Hers Health Inc (HIMS)?
The market capitalisation of Hims Hers Health Inc is $7.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hims Hers Health Inc (HIMS)?
The price-to-sales ratio of Hims Hers Health Inc is 3.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hims Hers Health Inc (HIMS)?
Earnings per share at Hims Hers Health Inc are $−0.0800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hims Hers Health Inc (HIMS)?
The net margin of Hims Hers Health Inc is 5.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hims Hers Health Inc (HIMS)?
The return on equity (ROE) of Hims Hers Health Inc is −2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hims Hers Health Inc (HIMS)?
On an EBIT basis the return on assets of Hims Hers Health Inc is −7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hims Hers Health Inc (HIMS)?
The operating margin of Hims Hers Health Inc is −7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hims Hers Health Inc (HIMS)?
Revenue at Hims Hers Health Inc is growing +3.8% versus a year earlier (3y avg +64.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hims Hers Health Inc (HIMS)?
Earnings per share at Hims Hers Health Inc are growing −17.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hims Hers Health Inc (HIMS) carry?
The net debt of Hims Hers Health Inc is $1.0B (fiscal year 2025, ≈ 14.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hims Hers Health Inc in the live analysis
One click puts Hims Hers Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026